IN THIS ISSUE
Horizon 2020, the European Union’s research and innovation programme, is entering its final year. But how has the money been used to drive pharma developments in the region? We round up the most successful and innovative projects to emerge from scheme. Plus, we examine the potential consequences of matching US drug prices with the rest of the developing world.
Also in this issue, we learn about the unique testing process implemented by US pharmacy Valisure to ensure drug quality, investigate the understanding of ageing in drug development, and find out how in-space drug manufacturing is being floated as a way to maintain the health of astronauts on deep space missions.
Plus, we explore the science behind the surprise return of Biogen’s Alzheimer’s treatment aducanumab, take a look at the future of EDS treatment, examine pharma’s role in improving access to medicines, and get insights into the patient agenda and IDMP from Iperion Life Sciences Consultancy.
Eloise McLennan, editor